

2024 SAMPLE CHARACTERISTICS



EDRS

Ecstasy and Related Drugs Reporting System



23 years Male

The median age in 2024 was 23, and 55% identified as male.

Current students **39%**
Full time work **30%**
Unemployed **23%**



In the 2024 sample, 39% were current students, 30% were employed full time and 23% were unemployed.



Ecstasy



Cocaine



Other stimulants


Participants were recruited on the basis that they had consumed ecstasy and/or other illicit stimulants at least monthly in the past 6 months.

DRUG-RELATED HARMS AND RISKS


Drug driving **50%**
Drink driving **29%**



Among recent drivers, 50% reported driving a vehicle within 3 hours of consuming illicit drugs and 29% while over the legal limit of alcohol.




Percentage who reported past year non-fatal depressant and stimulant overdose.



Percentage who obtained an AUDIT score of eight or more, indicative of past year hazardous alcohol use.

Two or more drugs **82%**
Depressants & stimulants **29%**
Depressants, stimulants & cannabis **14%**



In 2024, 82% reported using two or more drugs on the last occasion of ecstasy or related drug use: the most commonly used combination of drug classes was depressants and stimulants (29%).

OTHER BEHAVIOURS

58%


Self reported MH issue

36%


Seen a MH professional

Percentage who self-reported mental health problems and treatment seeking in the six months preceding interview.


Anxiety **68%**
Depression **62%**
ADHD **25%**



Among those who reported a mental health problem, the three most common mental health issues were anxiety, depression and ADHD.




Percentage who reported that they or someone else had tested the content and/or purity of their illicit drugs in Australia in the past year.




28% of the sample reported experiencing stigma because of their illicit drug use in the six months preceding interview, most commonly from police.

PAST 6 MONTH USE OF SELECT DRUGS


Ketamine




LSD




Hallucinogenic mushrooms/psilocybin




GHB/GBL/1,4-BD



Amyl Nitrite



Nitrous oxide (nangs)




E-cigarettes




ECSTASY


FORM of ecstasy



Past 6 month use of ecstasy capsules, crystal, pills, and powder in 2024.



Of those who had recently used any ecstasy, 17% reported weekly or more frequent use, stable from 2023 (14%).




Median amounts of ecstasy consumed in a 'typical' session.




In 2024, more participants perceived the availability of all forms of ecstasy as 'easy' or 'very easy' relative to 2023.

METHAMPHETAMINE


FORM of methamphetamine




Past 6 month use of any methamphetamine, crystal, powder and base in 2024.



Of those who had recently used any methamphetamine, 42% reported weekly or more frequent use, stable from 2023 (38%).




87% of participants who had recently used crystal smoked it. Of those who had recently used powder, 77% snorted it.




Percentage who perceived crystal methamphetamine as being 'easy' or 'very easy' to obtain.

COCAINE




Past 6 month use of any cocaine remained stable between 2023 and 2024.



Of those who had recently consumed cocaine, 12% reported weekly or more frequent use, stable from 2023 (9%).




The median reported price for a gram of cocaine.




Percentage who perceived cocaine as being 'easy' or 'very easy' to obtain.



CANNABIS AND/OR CANNABINOID-RELATED PRODUCTS



Past 6 month use of non-prescribed cannabis and/or cannabinoid-related products was stable between 2023 and 2024.



Of those who had recently used non-prescribed cannabis, 62% reported weekly or more frequent use, stable from 2023 (58%).



Percentage who perceived cannabis/cannabinoid-related products as being 'easy' or 'very easy' to obtain (stable from 2023).